RAZADYNE ER Drug Patent Profile

When do Razadyne Er patents expire, and what generic alternatives are available?

Razadyne Er is a drug marketed by Janssen Pharms and is included in one NDA.

The generic ingredient in RAZADYNE ER is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the galantamine hydrobromide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Razadyne Er

A generic version of RAZADYNE ER was approved as galantamine hydrobromide by BARR on August 28^th, 2008.

Summary for RAZADYNE ER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	21
Patent Applications:	880
Drug Prices:	Drug price information for RAZADYNE ER
DailyMed Link:	RAZADYNE ER at DailyMed

See drug prices for RAZADYNE ER

Recent Clinical Trials for RAZADYNE ER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Vanderbilt University Medical Center	Phase 1
Vanderbilt University	Phase 1/Phase 2
Doris Duke Charitable Foundation	Phase 1/Phase 2

See all RAZADYNE ER clinical trials

Paragraph IV (Patent) Challenges for RAZADYNE ER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	16 mg and 24 mg	021615	1	2006-03-11
RAZADYNE ER	Extended-release Capsules	galantamine hydrobromide	8 mg	021615	1	2006-03-02

US Patents and Regulatory Information for RAZADYNE ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-002	Apr 1, 2005		DISCN	Yes	No
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005		DISCN	Yes	No

Expired US Patents for RAZADYNE ER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005	4,663,318
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005	7,160,559
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-001	Apr 1, 2005	7,160,559
Janssen Pharms	RAZADYNE ER	galantamine hydrobromide	CAPSULE, EXTENDED RELEASE;ORAL	021615-003	Apr 1, 2005	4,663,318

International Patents for RAZADYNE ER

See the table below for patents covering RAZADYNE ER around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	9916835
Estonia	200100319
China	100370990
Austria	252386

Supplementary Protection Certificates for RAZADYNE ER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236684	C00236684/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0236684	C300140	Netherlands		PRODUCT NAME: GALANTAMINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER GALANTAMINE HYDROBROMIDE; NAT. REGISTRATION NO/DATE: RVG 29073 - RVG 29076 20030702; FIRST REGISTRATION: SE 15561 - 15565 20000225
0236684	3/2001	Austria		PRODUCT NAME: GALANTAMIN ODER SAEUREADDITIONSSALZE DAVON; NAT. REGISTRATION NO/DATE: 1-23748, 1-23749, 1-23750, 1-23751 20000822; FIRST REGISTRATION: SE 15561, 15562, 15563,15565 20000301
0236684	SPC/GB00/033	United Kingdom		PRODUCT NAME: GALANTHAMINE OR ACID ADDITION SALTS THEREOF; REGISTERED: SE 15561 20000301; SE 15562 20000301; SE 15563 20000301; SE 15565 20000301; UK PL08557/0039 20000914; UK PL08557/0040 20000914; UK PL08557/0041 20000914; UK PL08557/0042 20000914

Market Dynamics and Financial Trajectory for Razadyne ER

Last updated: January 27, 2026

Executive Summary

Razadyne ER (galantamine extended-release) is an approved treatment for mild to moderate Alzheimer’s disease. Since its FDA approval in 2001 and subsequent reformulation as an extended-release (ER) product in 2010, Razadyne ER has maintained a modest but stable position within the cholinesterase inhibitor (ChEI) segment of dementia therapeutics. This report analyzes current market dynamics, competitive landscape, regulatory factors, and future financial trajectories to inform stakeholders about Razadyne ER’s prospects in the evolving Alzheimer’s treatment market.

---

Market Overview

Alzheimer's Disease Market Context

The global Alzheimer’s disease (AD) therapeutics market was valued at approximately $4.3 billion in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.2% from 2023 to 2030[1]. Driven by aging populations, the increasing prevalence of AD—estimated to affect over 55 million people worldwide in 2023[2]—and advancements in symptomatic treatments, the market remains competitive.

Key Therapeutic Class: Cholinesterase Inhibitors

Razadyne ER belongs to the class of cholinesterase inhibitors, which also includes donepezil, rivastigmine, and galantamine (immediate-release). These drugs primarily target symptomatic cognitive decline, with limited disease-modifying effects.

Drug Name	Formulation	Approved Indications	Market Share (2022)	Route of Administration	Patent Status
Razadyne ER	Oral, extended-release	Mild to moderate AD	~5% (estimated)	Oral	Patent expired (2019 for IR; ER exclusivity until 2022)
Donepezil	Oral	Mild to severe AD	~50%	Oral	Patent expired (2014)
Rivastigmine	Oral, patch	Mild to moderate AD	~20%	Oral, topical	Patent expired (2017 for IR, 2018 for patch)
Galantamine IR	Oral	Mild to moderate AD	~15%	Oral	Patent expired (2018)

---

Current Market Dynamics for Razadyne ER

Competitive Positioning

Razadyne ER’s market share remains modest, partly due to:

• Patent Expiry: Loss of market exclusivity post-2019 diminishes pricing power.
• Generic Competition: Most competing ChEIs are available generically, influencing price sensitivity and prescribing preferences.
• Physician Preference: Donepezil's once-daily dosing and established efficacy underpin its dominance.
• Limited Advancement: Razadyne ER’s incremental differentiation reduces appeal among clinicians seeking newer therapies.

Regulatory and Patent Landscape

• Patent Status: Razadyne ER received FDA approval for extension until 2022; patent expiration facilitated entry of generics.
• Orphan Drug and Line Extensions: No recent orphan or line extension approvals bolster exclusivity.
• Pricing and Reimbursement: With loss of patent protections, Razadyne ER faces reimbursement challenges, and price competition from generics has pressured margins.

Market Drivers and Barriers

Drivers	Barriers
Aging global population increases AD prevalence	Generic competition reduces profit margins
Growing acceptance of combination therapies	Limited symptomatic efficacy compared to newer agents
Advances in diagnostic techniques leading to earlier detection	Lack of disease-modifying options for early-stage AD

Therapeutic Alternatives and Pipeline

The advent of disease-modifying therapies (DMTs), such as Aduhelm (aducanumab) and Lecanemab, signals a shift toward personalized medicine and biomarker-driven diagnosis, potentially decreasing reliance on symptomatic therapies like Razadyne ER over time[3].

---

Financial Trajectory Outlook

Historical Revenue Performance

Year	Estimated Global Sales	Notes
2010	~$150 million	Post-ER launch, peak sales
2015	~$100 million	Decline due to generic competition
2020	~$70 million	Accelerated decline, patent expiry impacts

Projected Revenue Trends (2023-2030)

Year	Expected Market Share (%)	Estimated Revenue (USD Millions)	Assumptions
2023	2-3%	$20–30	Further generic penetration, slow market decline
2025	1-2%	$10–20	Market saturation, minimal growth
2030	<1%	<$10	Diminishing relevance in AD therapy

Key Factors Affecting Financial Trajectory

• Generic Competition: Dominance of cheaper generics constrains pricing.
• Pricing Strategies: Premium pricing less feasible; focus on niche or bundle offerings.
• Regulatory Actions: Any early patent litigations or patent extensions could alter projections.
• Pipeline Developments: New formulations, line extensions, or combination strategies might alter revenue streams.

---

Comparative Analysis with Competitors

Feature	Razadyne ER	Donepezil	Rivastigmine	Lecanemab (Biogen/Eisai, NDA expected in 2023)
Patent Status	Expired (2019)	Expired (2014)	Expired (2017) IR, 2018 patch	Pending approval
Dosing	Once daily	Once daily	BID or patch	N/A
Efficacy	Moderate	Moderate	Moderate	Moderate (potential disease-modifying)
Market Share (2022)	~5%	~50%	~20%	N/A

Strategic Implications

• Revitalization: Potential for repositioning Razadyne ER through line extensions, combination therapies, or novel delivery systems.
• Market Focus: Target niche markets such as early-stage diagnosis or specific patient subsets resistant to other therapies.
• Partnerships: Licensing agreements and collaborations could extend the product lifecycle and market presence.
• Innovation: Investing in formulations with improved pharmacokinetics or biomarker-based targeting may restore competitive relevance.

---

FAQs

1. Will Razadyne ER regain market share post-patent expiry?
Unlikely, given the competitive landscape dominated by generics; market dynamics favor lower-cost alternatives with established efficacy.

2. Are there ongoing clinical trials for Razadyne ER?
Currently, no significant late-stage trials are publicly announced, suggesting limited pipeline activity for new indications or formulations.

3. How does Razadyne ER compare in efficacy to other cholinesterase inhibitors?
Efficacy profiles are similar across ChEIs, generally providing modest symptomatic benefits with no clear superiority.

4. Can Razadyne ER benefit from new Alzheimer’s treatment paradigms?
Potentially, if combined with disease-modifying therapies or in targeted populations; however, its primary role remains symptomatic management.

5. What is the outlook for Razadyne ER in regions outside the US?
Market opportunities are constrained by local regulatory approval status, reimbursement policies, and competitive dynamics, often mirroring the US market.

---

Key Takeaways

• Razadyne ER’s market share is declining due to patent expiration, generic competition, and shifting therapeutic paradigms.
• Revenue projections indicate continued, albeit diminishing, contributions through 2030, primarily driven by residual prescribing.
• Future growth unlikely without strategic repositioning, pipeline innovation, or combination therapy development.
• The broader Alzheimer’s market’s evolution toward disease-modifying treatments may further diminish the role of symptomatic agents like Razadyne ER.
• Stakeholders should consider diversification and integrated pathways to sustain profitability in a highly competitive environment.

---

References

[1] Research and Markets. "Global Alzheimer’s Disease Therapeutics Market Outlook," 2022.
[2] Alzheimer’s Disease International. "World Alzheimer Report 2023," 2023.
[3] Biogen and Eisai. "Lecanemab NDA Submission," 2023.